Our history

Founded in 2014, aptaTargets spun-out of Aptus Biotech, an aptamer technology platform. aptaTargets started a drug development program collaborating with the Complutense University and the Ramon y Cajal Hospital. aptaTargets raised a Series A in 2017, from Caixa Capital Risc and Inveready Asset Management, specialized European biotechnology venture capital funds.

In June 2019, aptaTargets initiated a First-in-Human clinical trial in healthy volunteers.

 

APTATARGETS
clinical-stage biopharmaceutical using aptamer technology for targeting acute indications.
ApTOLL
(Lead-candidate) is a neuroprotective drug for acute ischemic stroke by targeting inflammation in the acute phase.
Targeting indications
where inflammation causes significant damage, including ischemic stroke, intracerebral hemorrhage, myocardial infarction, and multiple sclerosis.